Legal Disclaimer
Cannabis laws change rapidly. This guide reflects the best available information as of May 2026. Always verify current law with official government sources before travelling or making medical decisions. This is not legal or medical advice.
50+
countries with medical programmes
38
US states with medical access
20+
European countries with programmes
6
US states with zero access
Medical cannabis access has expanded dramatically since 2015. Today, more than 50 countries have some form of legal medical cannabis programme — from comprehensive national systems like Canada and Germany to narrow compassionate-use pathways covering only a handful of specific conditions. Across the United States, 38 states now permit medical cannabis, with 24 states plus D.C. having gone further to legalise adult recreational use.
But "legal" rarely means "easy to access." Insurance coverage, product availability, qualifying conditions, and prescription costs vary enormously. This guide breaks down the real-world access picture by region.
Jump to section
United States — All 50 States
At the federal level, cannabis remains a Schedule I controlled substance. Each state independently sets its own programme. Below is the 2025 status for all 50 states plus D.C.
Adult-Use
Medical Only
CBD/Limited
No Programme
| State | Status | Medical? | Adult-Use? | Key Notes |
|---|---|---|---|---|
| Alaska | Adult-Use | Yes | Yes | Legal since 2015. Retail dispensaries operate statewide. Possession limit: 1 oz in public. |
| Alabama | Medical | Yes | No | Medical programme launched 2023. Limited conditions. Patient card required. |
| Arizona | Adult-Use | Yes | Yes | Prop 207 passed 2020. Retail sales started 2021. 1 oz possession limit. |
| Arkansas | Medical | Yes | No | Medical since 2016. Dispensaries statewide. Recreational failed ballot 2022. |
| California | Adult-Use | Yes | Yes | Prop 64 (2016). World's largest legal cannabis market. Medical since 1996 (first US state). |
| Colorado | Adult-Use | Yes | Yes | First state with adult-use retail (2012). Mature regulated market. |
| Connecticut | Adult-Use | Yes | Yes | Retail sales began 2023. Medical programme predates adult-use. |
| Delaware | Adult-Use | Yes | Yes | Adult-use signed 2023. Retail licensing ongoing. Possession decrim until retail opens. |
| Florida | Medical | Yes | No | Medical since 2016, large programme (>800,000 patients). Adult-use ballot 2024 failed (voted 56%, needed 60%). |
| Georgia | CBD/Limited | CBD only | No | Low-THC oil (<5% THC) for registered patients only. Limited conditions. |
| Hawaii | Medical | Yes | No | Medical since 2000. Dispensaries since 2016. Adult-use bills pending. |
| Idaho | No Programme | No | No | Fully illegal. One of only 6 states with no medical access of any kind. |
| Illinois | Adult-Use | Yes | Yes | Adult-use since 2020. First state to legalise via legislature (not ballot). |
| Indiana | CBD/Limited | CBD only | No | CBD products legal if hemp-derived with <0.3% THC. No medical programme. |
| Iowa | CBD/Limited | CBD only | No | Medical cannabidiol programme — low-THC oil (<3% THC) for qualifying conditions. |
| Kansas | No Programme | No | No | Fully illegal. No medical access of any kind. Legislature has blocked reform bills. |
| Kentucky | Medical | Yes | No | SB 47 signed 2023. Sales began January 2025. Dispensary network operational. |
| Louisiana | Medical | Yes | No | Medical programme active. Dispensaries operated by licensed pharmacies only. |
| Maine | Adult-Use | Yes | Yes | Adult-use retail open since 2020. Strong legacy of medical access since 1999. |
| Maryland | Adult-Use | Yes | Yes | Retail sales began July 2023. 1.5 oz possession limit for adults 21+. |
| Massachusetts | Adult-Use | Yes | Yes | First East Coast state with retail cannabis. Mature market since 2018. |
| Michigan | Adult-Use | Yes | Yes | One of the US's highest-volume markets. Prop 1 passed 2018. Retail since 2019. |
| Minnesota | Adult-Use | Yes | Yes | Adult-use signed 2023. Home cultivation and edibles allowed immediately. Retail sales 2025. |
| Mississippi | Medical | Yes | No | Medical programme since 2022. Dispensaries operational statewide. |
| Missouri | Adult-Use | Yes | Yes | Amendment 3 passed Nov 2022. Retail since Feb 2023. Large dispensary network. |
| Montana | Adult-Use | Yes | Yes | Adult-use since 2021. Retail sales began 2022. Rural distribution remains limited. |
| Nebraska | No Programme | No | No | Voters approved medical cannabis Nov 2024 (Initiative 437/438). Legislature implementing programme; no dispensaries yet. |
| Nevada | Adult-Use | Yes | Yes | Adult-use since 2017. Las Vegas has one of the densest dispensary markets globally. |
| New Hampshire | Medical | Yes | No | Medical since 2013. Adult-use legislation advancing in 2025 legislature. |
| New Jersey | Adult-Use | Yes | Yes | Question 1 passed 2020. Retail since April 2022. 6 oz home possession limit. |
| New Mexico | Adult-Use | Yes | Yes | Cannabis Regulation Act 2021. Retail since June 2021. No purchase quantity limit for adults. |
| New York | Adult-Use | Yes | Yes | MRTA signed 2021. Retail rollout slow; hundreds of licensed dispensaries now open in NYC region. |
| North Carolina | No Programme | No | No | CBD-only industrial hemp programme. No medical cannabis access. Reform stalled in legislature. |
| North Dakota | Medical | Yes | No | Medical since 2016. Adult-use ballot measures failed in 2018 and 2022. |
| Ohio | Adult-Use | Yes | Yes | Issue 2 passed Nov 2023. Retail sales began Aug 2024. 2.5 oz possession limit. |
| Oklahoma | Medical | Yes | No | One of the most open medical programmes — any condition with a doctor recommendation. Recreational failed 2023 ballot. |
| Oregon | Adult-Use | Yes | Yes | Retail since 2015. One of the earliest and most mature markets. Measure 110 decriminalised all drugs 2020. |
| Pennsylvania | Medical | Yes | No | Large medical programme (>400,000 patients). Adult-use bills advancing in 2025. |
| Rhode Island | Adult-Use | Yes | Yes | Adult-use signed 2022. Retail since Dec 2022. 1 oz possession limit. |
| South Carolina | No Programme | No | No | Fully illegal. Hemp-derived CBD technically legal. Medical bills consistently blocked. |
| South Dakota | Medical | Yes | No | Medical since 2021. Governor blocked adult-use even after voters approved it (2020). Dispensaries operational. |
| Tennessee | CBD/Limited | CBD only | No | Hemp CBD legal. No medical programme. Cannabis possession criminal. |
| Texas | CBD/Limited | Very limited | No | Compassionate Use Programme: low-THC (<1%) for epilepsy, PTSD, cancer, terminal conditions. Very restrictive. Possession otherwise criminal. |
| Utah | Medical | Yes | No | Medical since 2018. State-licensed pharmacies only. No smoking allowed; products must be ingested or vaporized. |
| Vermont | Adult-Use | Yes | Yes | First state to legalise via legislature without ballot (2018). Retail sales since Oct 2022. |
| Virginia | Adult-Use | Yes | Yes | Adult-use signed 2021. Retail since Jan 2024. 1 oz possession limit in public. |
| Washington | Adult-Use | Yes | Yes | I-502 passed 2012 (alongside Colorado). One of the most regulated markets. High excise taxes. |
| West Virginia | Medical | Yes | No | Medical since 2017. Dispensaries operational. Opioid-affected state; medical cannabis seen as alternative pain management. |
| Wisconsin | CBD/Limited | CBD only | No | Hemp CBD legal. No medical programme. Governor supports legalisation; Republican legislature blocks bills. |
| Wyoming | No Programme | No | No | Fully illegal. One of the most restrictive states. No decriminalisation. Significant penalties. |
| Washington D.C. | Adult-Use | Yes | Yes | Initiative 71 passed 2014. Legal to possess and gift; Congress blocked commercial retail for years. Gifting market active; licensed stores now operating. |
* Federal law: Cannabis remains Schedule I under the Controlled Substances Act. Possession on federal land (national parks, federal buildings, airports) is illegal in all states. Carrying cannabis across state lines is a federal offence even between two legal states.
Europe — Country by Country
No unified EU cannabis policy exists. Each member state sets its own laws. More than 20 European countries now permit some form of medical cannabis, though practical availability and insurance coverage vary enormously.
| Country | Medical Legal? | Adult-Use? | Prescription? | CBD Legal? | Key Notes |
|---|---|---|---|---|---|
| Germany | Yes — since 2017 | Partial (2024 CanG) | Yes | Yes | Adults may possess 25 g in public, 50 g at home, 3 plants. Social Clubs legal under CanG. GKV insurance may cover medical costs for qualifying patients. No commercial retail yet. |
| Netherlands | Yes — pharmacy | Tolerated | Yes | Yes | Coffeeshops tolerated under gedoogbeleid. Medical via Bedrocan in pharmacies. Regulated supply pilot (closed coffeeshop chain) active since 2023. |
| Malta | Yes | Yes — since 2021 | For medical | Yes | First EU country with adult-use legalisation. Up to 7 g public, 50 g home, 4 plants. Non-profit associations supply cannabis — no commercial retail. |
| Luxembourg | Limited | Partial — personal | N/A | Yes | Personal possession and home cultivation (4 plants) for adults legal. Commercial sales framework in development. Second EU country moving toward full legalisation. |
| Portugal | Yes — since 2018 | No (decrim) | Yes | Yes | All drugs decriminalised since 2001 (up to 25 g cannabis). Medical programme since 2018. Major licensed export industry. Products in pharmacies on prescription. |
| Spain | No formal programme | No (grey zone) | N/A | Yes | Cannabis Social Clubs tolerated in Catalonia & Basque Country. Personal cultivation decriminalised. No pharmacy medical programme. Sativex approved for MS. |
| Italy | Yes | No | Yes | Yes (<0.6% THC) | Military pharmaceutical institute (IMFC) produces medical cannabis. Chronic supply shortages mean most products are imported from Netherlands, Germany, Canada. |
| France | Permanent since 2024 | No | Yes | Yes (strict) | Medical pilot 2021 transitioned to permanent framework 2024. Pharmacy dispensing for specific conditions. Among Europe’s strictest general cannabis policies. |
| Czech Republic | Yes — since 2013 | No (decrim) | Yes | Yes | Up to 10 g possession and 5 plants decriminalised. Medical in pharmacies since 2013 (full out-of-pocket cost). Broader legalisation legislation advancing 2025. |
| Switzerland | Yes | Pilot only | Yes | Yes (<1% THC) | City-level adult-use pilots (Basel, Bern, Zurich, Geneva) active since 2023 under federal research framework. Highest CBD threshold in Europe (1% THC). Not EU member. |
| Austria | Yes | No | Yes | Yes (<0.3% THC) | Medical cannabis via prescription. Harm-reduction approach — possession may result in therapy referral rather than criminal charge. CBD shops widespread. |
| Denmark | Yes — permanent | No | Yes | Yes | Four-year pilot (2018–2022) became permanent medical programme. Major licensed exporter. Christiania (Copenhagen) historically tolerated cannabis market. |
| Poland | Yes — since 2017 | No | Yes | Yes | Medical cannabis imported and sold in pharmacies since 2017. One of Central Europe’s largest medical import markets. Access improving but costs remain high. |
| Greece | Yes — since 2017 | No | Yes | Yes | Licensed medical cultivation since 2018. Significant export industry. Recreational possession carries criminal penalties. |
| United Kingdom | Yes — since 2018 | No | Specialist only | Yes (<0.2% THC) | NHS rarely prescribes. Private prescriptions cost £500–£800+/month. For a step-by-step guide to medical cannabis access in the UK, see CannaCheck. Cannabis Class B — up to 5 years possession. No national decriminalisation. Not EU member. |
| Belgium | Sativex only | No | N/A | Yes | No formal medical programme. Possession up to 3 g de-prioritised in practice. CBD widely sold. Reform legislation advancing in parliament 2025. |
| Ireland | Limited (MAP) | No | Yes | Yes | Medical Access Programme (MAP) operational. Citizens’ Assembly recommended decriminalisation 2023. Legislation advancing. Recreational illegal. |
| Sweden | Sativex only | No | Yes | Restricted | Europe’s most restrictive approach. Zero tolerance. CBD in legal grey zone. No decriminalisation debate gaining traction. |
| Hungary | No | No | N/A | Restricted | Among EU’s harshest laws. Multi-year prison sentences even for minor possession. No reform at government level. |
| Romania | No | No | N/A | Hemp only | No medical programme. Criminal penalties for possession. No reform momentum. |
| Bulgaria | No | No | N/A | Hemp only | No medical programme. All cannabis use criminal. Industrial hemp legal. |
Americas (non-US)
| Country | Status | Key Details | Regulator |
|---|---|---|---|
| Canada | Adult-Use + Medical | First G7 country with full national legalisation (2018). Licensed retailers nationwide. Medical programme (ACMPR) provides enhanced access. Adults 18/19+ depending on province. | Health Canada / Cannabis Act |
| Mexico | Medical | Medical since 2017. COFEPRIS-licensed products in pharmacies. Personal use broadly decriminalised by Supreme Court rulings. | COFEPRIS |
| Colombia | Medical + Export | One of the world’s largest licensed producers. Medical access via prescription. Personal use up to 20 g broadly tolerated (Constitutional Court ruling). | Ministry of Justice / INVIMA |
| Uruguay | Adult-Use | First country to fully legalise (2013). Pharmacy purchase (residents only), social clubs, or home cultivation (6 plants). Tourists cannot purchase at pharmacies. | IRCCA / Law 19.172 |
| Argentina | Medical | REPROCANN programme: patients register and may self-cultivate or source from licensed associations. Covers pain, epilepsy, palliative care and more. | ANMAT / Law 27.350 |
| Jamaica | Decrim + Herb Houses | Possession up to 56 g: non-criminal fixed penalty. Rastafarian use exempted. Licensed herb houses sell to tourists. Medical programme operational. | Cannabis Licensing Authority |
| Brazil | Medical CBD | ANVISA-approved CBD and medicinal products by prescription. THC medicines require exceptional import authorisation. Decriminalised for personal use in practice. | ANVISA / RDC 327 (2019) |
| Chile | Medical | Medical programme since 2015. ISP-authorised products. Personal use decriminalised in practice. State-run cultivation for research. | ISP / Law 20.000 |
Asia-Pacific
The Asia-Pacific region ranges from highly progressive medical frameworks to some of the world’s strictest prohibition regimes. Penalties in countries like Singapore, Malaysia, and Indonesia can include the death penalty for trafficking.
| Country | Status | Key Details | Regulator |
|---|---|---|---|
| Australia | Medical | Medical since 2016. TGA schedules products; SAS-B pathway via specialist doctors. ACT allows personal adult-use possession since 2020 (1 oz). Domestic cultivation industry active. | TGA (Federal) / ODC |
| Thailand | Medical + Partial Decrim | Removed from narcotics list June 2022. Medical clinics and dispensaries widespread. Regulatory future uncertain after 2024 political changes — verify before travel. | FDA Thailand / MOPH |
| Israel | Medical (Major Programme) | 100,000+ registered patients. IMC-GMP certified producers export to EU, UK, and beyond. Personal use decriminalised. One of the world’s top cannabis export hubs. | IMCA (Israel Medical Cannabis Agency) |
| New Zealand | Medical | Medical access via any GP since 2020. Adult-use referendum failed 2020 (53% No). Sativex and CBD products Medsafe-approved. Accessible for pain, anxiety, and palliative care. | Medsafe / Ministry of Health |
| South Korea | Limited Medical | Only specific approved medicines (Epidiolex, Sativex, Marinol) via MFDS authorisation. No domestic programme. Possession carries severe criminal penalties. | MFDS |
| Japan | CBD Only | Cannabis prohibited under Cannabis Control Act. THC-free CBD in grey zone. Revised Act (2024) permits certain cannabinoid medicines. Possession penalties severe. | MHLW |
| India | Illegal | Cannabis illegal under NDPS Act 1985. Bhang (leaves/seeds) exempt and sold in licensed government shops. CBD regulated as food supplement. No medical programme. | NCB / NDPS Act |
Middle East & Africa
Africa is rapidly emerging as a significant licensed cultivation region for export markets. The Middle East is almost uniformly prohibitionist, with Israel as the major exception. Several African nations have issued export licences while maintaining domestic prohibition.
| Country | Status | Key Details |
|---|---|---|
| Israel | Medical (Strongest in Region) | Most developed programme in the Middle East. 100,000+ patients. IMC-GMP certified producers export globally. Personal use decriminalised. A leading global R&D hub for cannabinoid medicine. |
| South Africa | Medical Legal | Constitutional Court decriminalised personal use and cultivation in private (2018). SAHPRA medical licences since 2021. Commercial adult-use market not yet formally regulated. |
| Lesotho | Medical + Export | First African country to issue a cannabis cultivation licence (2017). Export-focused production under LNHC oversight. Small domestic medical programme. Altitude and climate make it attractive for licensed outdoor cultivation. |
| Zimbabwe | Medical + Export | Licensed cultivation for medical and scientific purposes since 2018. Primarily export-oriented. Domestic medical access limited. Enforcement against unlicensed possession remains strict. |
| Ghana | Developing | Parliament passed bill 2023 removing cannabis from most restrictive schedule. Medical and industrial programme framework being established. Recreational use remains illegal. |
| Morocco | Licensed Cultivation | Law 13-21 (2021) legalised licensed cultivation for medical, industrial, and cosmetic export. The Rif Mountains have produced cannabis resin for centuries. Recreational use remains criminal. |
| Lebanon | Licensed Cultivation | Law 178 (2020) legalised cultivation for industrial and medical export. Bekaa Valley has centuries-long cultivation history. Programme delayed by economic crisis. No domestic medical use formalised. |
| Rwanda | Export Licences | Export-focused cultivation licences issued since 2021 targeting European markets. No domestic medical access programme. Positioned as a premium African cultivation hub. Possession remains illegal. |
How to Access Medical Cannabis Abroad
- Check prescription recognition first. Most countries do not recognise foreign medical cannabis prescriptions. Germany, the Netherlands, and a few others permit limited cross-border recognition under strict conditions — verify with the destination country’s health ministry before travel.
- Expect local prescription requirements. Even in countries with active programmes, you will typically need a new prescription from a locally registered physician. Israel, Canada, Australia, and Thailand all require domestic registration or a new consultation.
- Pharmacies vs. dispensaries. In medical-only countries (Germany, Australia, New Zealand), products come from licensed pharmacies only. In Canada, Thailand, and Uruguay, separate dispensaries or clinic-affiliated retailers are the main access point.
- Foreign insurance rarely covers costs. Budget for full out-of-pocket expenses. Even where domestic insurance covers cannabis (Germany GKV, some Australian private funds), that coverage does not extend to foreign patients.
- Never carry cannabis across international borders. Even between two countries where it is legal, transporting cannabis internationally violates both the UN Single Convention and the laws of both countries. Always source locally or go without.